Nystatin: Difference between revisions
No edit summary |
No edit summary |
||
Line 73: | Line 73: | ||
<!--FDA-Labeled Indications and Dosage (Pediatric)--> | <!--FDA-Labeled Indications and Dosage (Pediatric)--> | ||
|fdaLIADPed====== | |fdaLIADPed======Candidiasis of skin, Cutaneous and mucocutaneous infections===== | ||
* Dosing Information | * Dosing Information | ||
Line 79: | Line 79: | ||
:* Dosage | :* Dosage | ||
===== | =====Oropharyngeal candidiasis===== | ||
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. | ||
Line 332: | Line 332: | ||
<!--Patient Counseling Information--> | <!--Patient Counseling Information--> | ||
|packLabel=[[File:Nystatin pdp.png|600px|thumbnail|left]] | |||
{{clear}} | |||
[[File:Nystatin label.png|600px|thumbnail|left]] | |||
{{clear}} | |||
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | ||
Revision as of 18:39, 6 November 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
Title
See full prescribing information for complete Boxed Warning.
ConditionName:
|
Overview
Nystatin is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include .
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Nystatin Cream USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.
Nystatin Cream USP is not indicated for systemic, oral, intravaginal or ophthalmic use.
Candidal vulvovaginitis
- Dosing Information
- Dosage
Candidiasis of skin, Cutaneous and mucocutaneous infections
- Dosing Information
- Dosage
Gastrointestinal candidiasis, Non-esophageal
- Dosing Information
- Dosage
Oropharyngeal candidiasis
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Nystatin in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Nystatin in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Candidiasis of skin, Cutaneous and mucocutaneous infections
- Dosing Information
- Dosage
Oropharyngeal candidiasis
There is limited information regarding FDA-Labeled Use of Nystatin in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Nystatin in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Nystatin in pediatric patients.
Contraindications
- Condition1
Warnings
Title
See full prescribing information for complete Boxed Warning.
ConditionName:
|
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Nystatin in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Nystatin in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Nystatin in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Nystatin during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Nystatin with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Nystatin with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Nystatin with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Nystatin with respect to specific gender populations.
Race
There is no FDA guidance on the use of Nystatin with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Nystatin in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Nystatin in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Nystatin in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Nystatin in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Nystatin in the drug label.
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Nystatin in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Nystatin in the drug label.
Pharmacology
Mechanism of Action
Structure
Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. The molecular formula is C47H75NO17, and the molecular weight is 926.13.
Structural formula:
Nystatin Cream USP is for dermatologic use.
Nystatin Cream USP for topical use, contains 100,000 USP nystatin units per gram. Inactive ingredients: emulsifying wax, glycerin, isopropyl myristate, lactic acid, purified water, sodium hydroxide, and sorbic acid.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Nystatin in the drug label.
Pharmacokinetics
Nystatin Cream USP is not absorbed from intact skin or mucous membrane.
Microbiology
Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsisglabrata, Tricophytonrubrum, T. mentagrophytes.
Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.
Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Nystatin in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Nystatin in the drug label.
How Supplied
Storage
There is limited information regarding Nystatin Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Nystatin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Nystatin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Nystatin in the drug label.
Precautions with Alcohol
- Alcohol-Nystatin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Nystatin |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}} |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Nystatin |Label Name=Nystatin11.png
}}
{{#subobject:
|Label Page=Nystatin |Label Name=Nystatin11.png
}}